My ePortfolio Register   

Initial results of inhibitor combination against breast and gynaecologic cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 532

Dr Shannon Westin - MD Anderson Cancer Center, Houston, Texas

Dr Westin talks with ecancer at the ESMO 2017 Congress in Madrid about the phase I expansion of olaparib and a novel AKT inhibitor (AZD5363) in recurrent ovarian, endometrial and triple negative breast cancer. 

She notes this as one of the arms in the OCTOPUS trial, and details the dosage and cohort composure of patients recruited so far.

Dr Westin describes the tolerance of this combination as promising, and notes other arms and combinations within the trial evaluating alternative combinations.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence